Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | PPARD | Q03181 | 9/20 | 0.37 |
| ▸ | PPARA | Q07869 | 8/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035372 | 0.98 | PPARD (0.36) | SMN1; SMN2KDM4EPPARDPPARALMNA | |
| SCHEMBL6035388 | 0.96 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4EPPARDPPARALMNA | |
| SCHEMBL6035191 | 0.92 | MRGPRX4 (0.35) | PPARDPPARAGCGRLTB4RTHRA | |
| SCHEMBL6034853 | 0.91 | PPARD (0.42) | PPARDPPARALTB4RDGAT1NR3C1 | |
| SCHEMBL6034689 | 0.90 | PPARD (0.36) | SMN1; SMN2PPARDPPARAGCGRHPGD | |
| SCHEMBL6035777 | 0.90 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4EPPARDPPARALMNA | |
| SCHEMBL6035370 | 0.89 | GCGR (0.37) | SMN1; SMN2KDM4EPPARDPPARALMNA | |
| SCHEMBL6036323 | 0.88 | LTB4R (0.38) | KDM4EPPARDPPARAGCGRLTB4R | |
| SCHEMBL6035849 | 0.88 | MLYCD (0.36) | PPARDPPARAGCGRLTB4RPPARG | |
| SCHEMBL6034858 | 0.87 | GCGR (0.36) | SMN1; SMN2KDM4EPPARDPPARALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | claimed |
| US-7932289-B2 | Remedy for diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20080319077-A1 | Remedy for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-12-25 | — | — | US | disclosed |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080319077-A1 | Remedy for Diabetes | GPR119, GLP1R, GPR65 | SMN1; SMN2 2497/4885KDM4E 3305/4885PPARD 48/4885 |
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | SMN1; SMN2 4408/4885KDM4E 509/4885PPARD 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.